Imatinib mesylate (Gleevec™) in the treatment of diffuse cutaneous systemic sclerosis: results of a 24-month open label, extension phase, single-centre trial

J. Gordon, U. Udeh, K. Doobay, C. Magro, H. Wildman, M. Davids, J. N. Mersten, W. T. Huang, S. Lyman, M. K. Crow, R. F. Spiera

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

OBJECTIVES: We aimed to assess the long-term safety and tolerability of imatinib in diffuse cutaneous systemic sclerosis (dcSSc).

METHODS: In this open-label, single-arm, extension-phase clinical trial, patients continued imatinib for 24 months following 12 months of initial treatment.

RESULTS: Seventeen patients were enrolled. Forty of 92 adverse events (AE) and 0/6 serious (S) AEs were possibly related to medication. The MRSS decreased from a median of 21 to 16, (p=0.002).

CONCLUSIONS: This study demonstrates long-term safety and tolerability of imatinib in a substantial proportion of patients with dcSSc. This is important in evaluating the relevance of this therapy in a chronic disease such as SSc.

Original languageEnglish
Pages (from-to)S-189-93
JournalClinical and experimental rheumatology
Volume32
Issue number6
Publication statusPublished - Nov 1 2014

Fingerprint

Diffuse Scleroderma
Safety
Chronic Disease
Therapeutics
Clinical Trials
Imatinib Mesylate

All Science Journal Classification (ASJC) codes

  • Rheumatology
  • Immunology and Allergy
  • Immunology

Cite this

Imatinib mesylate (Gleevec™) in the treatment of diffuse cutaneous systemic sclerosis : results of a 24-month open label, extension phase, single-centre trial. / Gordon, J.; Udeh, U.; Doobay, K.; Magro, C.; Wildman, H.; Davids, M.; Mersten, J. N.; Huang, W. T.; Lyman, S.; Crow, M. K.; Spiera, R. F.

In: Clinical and experimental rheumatology, Vol. 32, No. 6, 01.11.2014, p. S-189-93.

Research output: Contribution to journalArticle

Gordon, J, Udeh, U, Doobay, K, Magro, C, Wildman, H, Davids, M, Mersten, JN, Huang, WT, Lyman, S, Crow, MK & Spiera, RF 2014, 'Imatinib mesylate (Gleevec™) in the treatment of diffuse cutaneous systemic sclerosis: results of a 24-month open label, extension phase, single-centre trial', Clinical and experimental rheumatology, vol. 32, no. 6, pp. S-189-93.
Gordon, J. ; Udeh, U. ; Doobay, K. ; Magro, C. ; Wildman, H. ; Davids, M. ; Mersten, J. N. ; Huang, W. T. ; Lyman, S. ; Crow, M. K. ; Spiera, R. F. / Imatinib mesylate (Gleevec™) in the treatment of diffuse cutaneous systemic sclerosis : results of a 24-month open label, extension phase, single-centre trial. In: Clinical and experimental rheumatology. 2014 ; Vol. 32, No. 6. pp. S-189-93.
@article{3499163469c443cd90556d40888e937f,
title = "Imatinib mesylate (Gleevec™) in the treatment of diffuse cutaneous systemic sclerosis: results of a 24-month open label, extension phase, single-centre trial",
abstract = "OBJECTIVES: We aimed to assess the long-term safety and tolerability of imatinib in diffuse cutaneous systemic sclerosis (dcSSc).METHODS: In this open-label, single-arm, extension-phase clinical trial, patients continued imatinib for 24 months following 12 months of initial treatment.RESULTS: Seventeen patients were enrolled. Forty of 92 adverse events (AE) and 0/6 serious (S) AEs were possibly related to medication. The MRSS decreased from a median of 21 to 16, (p=0.002).CONCLUSIONS: This study demonstrates long-term safety and tolerability of imatinib in a substantial proportion of patients with dcSSc. This is important in evaluating the relevance of this therapy in a chronic disease such as SSc.",
author = "J. Gordon and U. Udeh and K. Doobay and C. Magro and H. Wildman and M. Davids and Mersten, {J. N.} and Huang, {W. T.} and S. Lyman and Crow, {M. K.} and Spiera, {R. F.}",
year = "2014",
month = "11",
day = "1",
language = "English",
volume = "32",
pages = "S--189--93",
journal = "Clinical and Experimental Rheumatology",
issn = "0392-856X",
publisher = "Clinical and Experimental Rheumatology S.A.S.",
number = "6",

}

TY - JOUR

T1 - Imatinib mesylate (Gleevec™) in the treatment of diffuse cutaneous systemic sclerosis

T2 - results of a 24-month open label, extension phase, single-centre trial

AU - Gordon, J.

AU - Udeh, U.

AU - Doobay, K.

AU - Magro, C.

AU - Wildman, H.

AU - Davids, M.

AU - Mersten, J. N.

AU - Huang, W. T.

AU - Lyman, S.

AU - Crow, M. K.

AU - Spiera, R. F.

PY - 2014/11/1

Y1 - 2014/11/1

N2 - OBJECTIVES: We aimed to assess the long-term safety and tolerability of imatinib in diffuse cutaneous systemic sclerosis (dcSSc).METHODS: In this open-label, single-arm, extension-phase clinical trial, patients continued imatinib for 24 months following 12 months of initial treatment.RESULTS: Seventeen patients were enrolled. Forty of 92 adverse events (AE) and 0/6 serious (S) AEs were possibly related to medication. The MRSS decreased from a median of 21 to 16, (p=0.002).CONCLUSIONS: This study demonstrates long-term safety and tolerability of imatinib in a substantial proportion of patients with dcSSc. This is important in evaluating the relevance of this therapy in a chronic disease such as SSc.

AB - OBJECTIVES: We aimed to assess the long-term safety and tolerability of imatinib in diffuse cutaneous systemic sclerosis (dcSSc).METHODS: In this open-label, single-arm, extension-phase clinical trial, patients continued imatinib for 24 months following 12 months of initial treatment.RESULTS: Seventeen patients were enrolled. Forty of 92 adverse events (AE) and 0/6 serious (S) AEs were possibly related to medication. The MRSS decreased from a median of 21 to 16, (p=0.002).CONCLUSIONS: This study demonstrates long-term safety and tolerability of imatinib in a substantial proportion of patients with dcSSc. This is important in evaluating the relevance of this therapy in a chronic disease such as SSc.

UR - http://www.scopus.com/inward/record.url?scp=85006237832&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85006237832&partnerID=8YFLogxK

M3 - Article

C2 - 25152211

AN - SCOPUS:85006237832

VL - 32

SP - S-189-93

JO - Clinical and Experimental Rheumatology

JF - Clinical and Experimental Rheumatology

SN - 0392-856X

IS - 6

ER -